Cargando…
A Single Dose of Anti-HBsAg Antibody-Encoding mRNA-LNPs Suppressed HBsAg Expression: a Potential Cure of Chronic Hepatitis B Virus Infection
Hepatitis B virus (HBV) infection is a serious global health issue with more than 250 million chronic carriers. It causes liver diseases such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). Persistent suppression of the HBV surface antigen (HBsAg) is necessary for a functi...
Autores principales: | Chen, Binfan, Chen, Yuchen, Li, Jian, Wang, Chunyu, Song, Wenping, Wen, Yumei, Lin, Jinzhong, Wu, Yanling, Ying, Tianlei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426588/ https://www.ncbi.nlm.nih.gov/pubmed/35862767 http://dx.doi.org/10.1128/mbio.01612-22 |
Ejemplares similares
-
Performance Evaluation of an Improved HBsAg Assay (HBsAg NEXT) for the Detection of HBsAg Levels
por: Gupta, Ekta, et al.
Publicado: (2023) -
Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon
por: Li, Hong, et al.
Publicado: (2022) -
Comparison of the Clinical Features of Hepatitis A between HBsAg-Positive and HBsAg-Negative Patients
por: Kim, Kwang Min, et al.
Publicado: (2011) -
Dilemma of HBsAg seroconversion in chronic hepatitis B infection: Dilemma of HBsAg in chronic HBV
por: Alavian, Seyed Moayed, et al.
Publicado: (2011) -
Contribution of NK cells to HBsAg seroconversion in inactive HBsAg carriers following pegylated IFN therapy
por: Cao, Zhenhuan, et al.
Publicado: (2020)